ArticleDisease models & mechanisms2026
Functional characterization of furin-mediated lipoprotein lipase cleavage.
Article in Disease models & mechanisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lipoprotein lipase (LPL) is the rate-limiting enzyme that hydrolyzes triglycerides within circulating lipoproteins. LPL dysfunction leads to familial LPL deficiency, which is characterized by chylomicronemia and high risk for acute pancreatitis. Although cell culture studies indicate that the protease furin inactivates LPL by cleavage, the physiological relevance of this process remains unclear. In this study, we investigated the impact of furin-mediated LPL cleavage in vivo using inducible knockout mouse models and gene therapy. After identifying the tissue-specific prevalence of LPL cleavage, we compared mice expressing a furin-resistant LPL mutant versus furin-sensitive LPL. Our results demonstrate that furin-resistant LPL lowers longitudinal plasma triglyceride levels without causing adverse effects, such as hepatic steatosis. These findings highlight that engineered furin resistance is a viable strategy to enhance the metabolic function of LPL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.